TY - JOUR
T1 - Role of the early secretory pathway in SARS-CoV-2 Infection
AU - Sicari, Daria
AU - Chatziioannou, Aristotelis
AU - Koutsandreas, Theodoros
AU - Sitia, Roberto
AU - Chevet, Eric
N1 - Funding Information:
E. Chevet was funded by the Institut National de la Santé et de la Recherche Médicale, Agence Nationale de la Recherche (eRARE-ERAAT), Institut National du Cancer (INCa PLBIO_2017, PLBIO_2018, and PLBIO_2019), and Fondation pour la Recherche Médicale (Equipe Labelisée 2018; Frm DEQ20180339169). D. Sicari was supported by an Associazione Italiana per la Ricerca sul Cancro fellowship for Abroad. A. Chatziioannou was supported by the project “ELIXIR-GR, The Greek Research Infrastructure for Data Management and Analysis in Life Sciences” (MIS 5002780), which is co-funded by the European Commission within the research infrastructures program of Horizon 2020 Framework Programme and national funds. T. Koutsandreas was supported by Marie Skłodowska-Curie actions grant MSCA-RISE-734749 (Interfere to Suppress or Promote IRE1 [INSPIRED]). R. Sitia was funded by Associazione Italiana per la Ricerca sul Cancro. The authors declare no competing financial interests.
Publisher Copyright:
© 2020 Journal of Virus Eradication.All right reserved.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/7
Y1 - 2020/7
N2 - Similar to other RNA viruses, SARS-CoV-2 must (1) enter a target/host cell, (2) reprogram it to ensure its replication, (3) exit the host cell, and (4) repeat this cycle for exponential growth. During the exit step, the virus hijacks the sophisticated machineries that host cells employ to correctly fold, assemble, and transport proteins along the exocytic pathway. Therefore, secretory pathway-mediated assemblage and excretion of infective particles represent appealing targets to reduce the efficacy of virus biogenesis, if not to block it completely. Here, we analyze and discuss the contribution of the molecular machines operating in the early secretory pathway in the biogenesis of SARS-CoV-2 and their relevance for potential antiviral targeting. The fact that these molecular machines are conserved throughout evolution, together with the redundancy and tissue specificity of their components, provides opportunities in the search for unique proteins essential for SARS-CoV-2 biology that could also be targeted with therapeutic objectives. Finally, we provide an overview of recent evidence implicating proteins of the early secretory pathway as potential antiviral targets with effective therapeutic applications.
AB - Similar to other RNA viruses, SARS-CoV-2 must (1) enter a target/host cell, (2) reprogram it to ensure its replication, (3) exit the host cell, and (4) repeat this cycle for exponential growth. During the exit step, the virus hijacks the sophisticated machineries that host cells employ to correctly fold, assemble, and transport proteins along the exocytic pathway. Therefore, secretory pathway-mediated assemblage and excretion of infective particles represent appealing targets to reduce the efficacy of virus biogenesis, if not to block it completely. Here, we analyze and discuss the contribution of the molecular machines operating in the early secretory pathway in the biogenesis of SARS-CoV-2 and their relevance for potential antiviral targeting. The fact that these molecular machines are conserved throughout evolution, together with the redundancy and tissue specificity of their components, provides opportunities in the search for unique proteins essential for SARS-CoV-2 biology that could also be targeted with therapeutic objectives. Finally, we provide an overview of recent evidence implicating proteins of the early secretory pathway as potential antiviral targets with effective therapeutic applications.
UR - http://www.scopus.com/inward/record.url?scp=85088881634&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088881634&partnerID=8YFLogxK
U2 - 10.1083/JCB.202006005
DO - 10.1083/JCB.202006005
M3 - Review article
C2 - 32725137
AN - SCOPUS:85088881634
VL - 219
JO - Journal of Cell Biology
JF - Journal of Cell Biology
SN - 0021-9525
IS - 9
M1 - 151984
ER -